Neuroimmunology Registry and Biobank

Sponsor
Charite University, Berlin, Germany
Study ID
NCT06958341
Status
Recruiting
Apply to this trial

Conditions

  • Ataxia
  • Encephalopathy
  • Epilepsy
  • Impaired Consciousness
  • Motor Neuropathy
  • Movement Disorders
  • Psychosis
  • Spasticity

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain. The registry was established with the following objectives: \[1\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \[2\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \[3\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \[4\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.

Key Dates

First listed
May 6, 2025
Start date
Feb 1, 2021
Status verified
May 2025
Primary completion
Jan 1, 2031
Completion
Jul 1, 2031

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: patients with suspected neuroimmunological disease
    patients with suspected neuroimmunological disease in whom a lumbar puncture is indicated for routine clinical work-up and for treatment decisions

Primary Outcome Measure

Screening for a panel of anti-neuronal antibodies via commercial assays [ Time Frame: at recruitment ]

Central Contacts

Find similar trials

Nationwide
Epilepsy trialsNeurology trialsBrain disorders trials

Related Studies